Sign up to our newsletter Subscribe
Improving the Fiscal and Political Sustainability of Health Systems through Integrated Population Needs-Based Planning

Sign up to our newsletter Subscribe
Biosimilars have similar, but not identical, structures to branded biologic drugs. Being comparable, but not interchangeable, they can differ in cost-effectiveness and accessibility. Increased competition, however, can reduce healthcare system costs.
An error has occurred, please try again later.